ONCS

OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

OncoSec to Present at the Raymond James Human Health Innovation Conference

OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma

OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors

OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development

OncoSec Medical Announces Proposed Public Offering of Common Stock